DocMorris AG/€DOCM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About DocMorris AG
DocMorris AG operates in the healthcare industry, focusing on providing pharmaceutical services as a leading online pharmacy in Europe. The company offers a wide range of prescription and over-the-counter medications, healthcare products, and services through its e-commerce platform. Founded in 2000, DocMorris is headquartered in Heerlen, the Netherlands. It holds a unique strategic position by leveraging digital technology to enhance customer convenience and streamline the medication procurement process. The company’s core strength lies in its extensive network and efficient delivery system, catering to a broad customer base across multiple European countries.
Ticker
€DOCM
Sector
Primary listing
XGAT
Employees
1,454
Headquarters
Frauenfeld, Switzerland
Website
DocMorris AG Metrics
BasicAdvanced
€339M
-
-€6.32
1.50
-
Price and volume
Market cap
€339M
Beta
1.5
52-week high
€42.40
52-week low
€6.40
Average daily volume
18K
Financial strength
Current ratio
3.251
Quick ratio
2.853
Long term debt to equity
63.775
Total debt to equity
64.652
Interest coverage (TTM)
-4.04%
Profitability
EBITDA (TTM)
-104.656
Gross margin (TTM)
21.68%
Net profit margin (TTM)
-11.38%
Operating margin (TTM)
-10.57%
Effective tax rate (TTM)
3.54%
Revenue per employee (TTM)
€781,800
Management effectiveness
Return on assets (TTM)
-7.70%
Return on equity (TTM)
-27.47%
Valuation
Price to revenue (TTM)
0.126
Price to book
0.64
Price to tangible book (TTM)
-44.47
Price to free cash flow (TTM)
-1.348
Free cash flow yield (TTM)
-74.21%
Free cash flow per share (TTM)
-5.186
Growth
Revenue change (TTM)
5.93%
Earnings per share change (TTM)
-28.87%
3-year revenue growth (CAGR)
-8.38%
10-year revenue growth (CAGR)
1.96%
3-year earnings per share growth (CAGR)
-36.81%
Bulls say / Bears say
DocMorris preliminary Q1 2025 results showed group revenues up 13.4% year-on-year to CHF 296.5 million and prescription revenues surging 52%, both slightly above consensus, underscoring strong demand in its core pharmacy business (Reuters via Investing.com)
The company reaffirmed guidance for over 10% sales growth in 2025 and issued a medium-term outlook targeting 20% annual revenue CAGR and an adjusted EBITDA breakeven by 2026, aligning with market expectations for sustainable growth (Reuters via Investing.com)
DocMorris secured a fully underwritten CHF 200 million capital increase via a rights offering, strengthening its balance sheet to fund targeted Rx marketing investments and potentially repay a CHF 95 million convertible bond, reducing refinancing risk (Reuters via Investing.com)
DocMorris reported an adjusted EBITDA loss of CHF 48.6 million in 2024, up from CHF 34.9 million the prior year, as higher marketing costs to boost digital prescriptions weighed on profitability (Reuters via Investing.com)
Baader Helvea downgraded DocMorris to “reduce,” citing an expected 125% share dilution from the planned CHF 200 million rights offering and guidance that remains below market expectations, highlighting potential downward pressure on the stock (Reuters)
Despite revenue growth, DocMorris’s net loss from continuing operations was €97.3 million in 2024, only modestly improved from €117.6 million the prior year, reflecting persistent financial headwinds (Reuters via Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DocMorris AG stock?
DocMorris AG (DOCM) has a market cap of €339M as of September 19, 2025.
What is the P/E ratio for DocMorris AG stock?
The price to earnings (P/E) ratio for DocMorris AG (DOCM) stock is 0 as of September 19, 2025.
Does DocMorris AG stock pay dividends?
No, DocMorris AG (DOCM) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next DocMorris AG dividend payment date?
DocMorris AG (DOCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DocMorris AG?
DocMorris AG (DOCM) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.